News for Gland Pharma Limited (GLAND.BO)

The Nifty Pharma index closed 0.41 per cent up at 21438.05.

The Nifty Pharma index was trading 0.19 per cent up at 20914.3.

The Nifty Pharma index closed 0.18 per cent down at 20874.3.

Aurobindo Pharma and Gland Pharma have fallen 9 per cent each in the past one week and 22-23 per cent in 2025 so far. Glenmark Pharma is down 9 per cent for the one month period and 14 per cent year-to-date.

RBI Governor Sanjay Malhotra acknowledged that US tariff measures have increased uncertainties, making it difficult to assess the impact on economic growth. While growth is improving, it remains below desired levels. The MPC has revised the FY26 GDP growth forecast downward by 20 basis points to 6.5%, citing headwinds from global trade and inflation.

President Trump's 26% tariffs on Indian goods have taken effect, impacting various sectors. While India anticipates a minor GDP hit and emphasizes domestic resilience, certain industries like electronics and textiles may benefit from the tariffs imposed on competitors. India's agricultural exports are expected to remain stable, potentially gaining a competitive edge.

Indian benchmark indices Nifty50 and Sensex initiated Wednesday on a downturn, mirroring a global sell-off fueled by escalating trade tensions. Investors are keenly awaiting the Reserve Bank of India's policy decision, with expectations of a potential interest rate cut. Wall Street's overnight tumble, triggered by U.S. tariff confirmations on Chinese imports, further contributed to market unease.

Indian pharmaceutical companies are crucial to the U.S. healthcare system, filling four out of every ten prescriptions in 2022. Reports indicate that Indian medicines saved the U.S. healthcare system USD 219 billion in 2022 and USD 1.3 trillion from 2013 to 2022. Over the next five years, Indian generics are expected to contribute an additional USD 1.3 trillion in savings.

The Nifty Pharma index was trading 1.24 per cent up at 20243.4.

Sensex tanks 800 pts, Nifty 50 trades below 23,000 level. Bajaj Finance & HDFC Bank lead gainers. ONGC, Hindalco, Tata Motors and Cipla drag

Granules India, Lupin, Gland Pharma and Cipla fell 5-6 per cent. Sun Pharmaceutical Industries slipped 5 per cent while Dr Reddy's Labs was down 4 per cent.

Large Indian drug manufacturers experienced relief as President Trump's administration decided against imposing expected reciprocal tariffs on pharmaceuticals, which could have significantly impacted their earnings. Analysts deem future tariffs unlikely due to potential drug shortages and the influence of major pharma companies investing in the US.

The exemption given to Indian pharmaceuticals is positive and, therefore, this segment is likely to witness buying, says analyst.

The Nifty Pharma index closed 0.87 per cent up at 20952.85.

The Nifty Pharma index was trading 0.4 per cent up at 20854.8.

The Nifty Pharma index closed 1.73 per cent down at 20771.8.

The Nifty Pharma index was trading 0.87 per cent down at 21090.2.

The Nifty Pharma index closed 1.05 per cent down at 21542.5.

The Nifty Pharma index was trading 0.79 per cent down at 21599.05.